Thiazole derivatives as kinase inhibitors
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
May 1, 2012
Grant Date -
Nov 25, 2010
app pub date -
Oct 16, 2007
filing date -
Oct 19, 2006
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
A series of thiazole derivatives which are substituted in the 2-position by a substituted morpholin-4-yl moiety, being selective inhibitors of P13 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully